Cell type dependent regulation of multidrug resistance-1 gene expression by AML1-ETO

Blood Cells, Molecules, and Diseases

Volumn 39, Issue 3, 2007, Pages 297-306

  Hines, Robert ^a   Boyapati, Anita ^a   Zhang, Dong Er ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AML ETO FUSION PROTEIN; HYBRID PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING SITE; CELL STRAIN K 562; CELL TYPE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE ACTIVATION; GENE DELETION; GENE EXPRESSION; GENE REPRESSION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION;

ANIMALS; CELL LINE; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DNA-BINDING PROTEINS; HUMANS; ONCOGENE PROTEINS, FUSION; P-GLYCOPROTEIN; PIPERAZINES; PROTO-ONCOGENE PROTEINS; PYRIMIDINES; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 34848904491     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2007.05.005     Document Type: Article

References (56)

1. Look A.T. Oncogenic transcription factors in the human acute leukemias. Science 278 (1997) 1059-1064
2. Licht J.D. AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML. Oncogene 20 (2001) 5660-5679
3. Downing J.R. The AML1-ETO chimaeric transcription factor in acute myeloid leukaemia: biology and clinical significance. Br. J. Haematol. 106 (1999) 296-308
4. Rowley J.D. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243 (1973) 290-293
5. Miyoshi H., et al. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J. 12 (1993) 2715-2721
6. Kamachi Y., et al. Purification of a mouse nuclear factor that binds to both the A and B cores of the polyomavirus enhancer. J. Virol. 64 (1990) 4808-4819
7. Thornell A., Hallberg B., and Grundstrom T. Binding of SL3-3 enhancer factor 1 transcriptional activators to viral and chromosomal enhancer sequences. J. Virol. 65 (1991) 42-50
8. Melnikova I.N., Crute B.E., Wang S., and Speck N.A. Sequence specificity of the core-binding factor. J. Virol. 67 (1993) 2408-2411
9. Okuda T., van Deursen J., Hiebert S.W., Grosveld G., and Downing J.R. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84 (1996) 321-330
10. Wang Q., Stacy T., Binder M., Marin-Padilla M., Sharpe A.H., and Speck N.A. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 3444-3449
11. Wang Q., et al. The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo. Cell 87 (1996) 697-708
12. Meyers S., Downing J.R., and Hiebert S.W. Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins: the runt homology domain is required for DNA binding and protein-protein interactions. Mol. Cell. Biol. 13 (1993) 6336-6345
13. Yergeau D.A., et al. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat. Genet. 15 (1997) 303-306
14. Okuda T., et al. Expression of a knocked-In AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood 91 (1998) 3134-3143
15. Meyers S., Lenny N., and Hiebert S.W. The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation. Mol. Cell. Biol. 15 (1995) 1974-1982
16. Frank R., Zhang J., Uchida H., Meyers S., Hiebert S.W., and Nimer S.D. The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B. Oncogene 11 (1995) 2667-2674
17. Amann J.M., et al. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol. Cell. Biol. 21 (2001) 6470-6483
18. Wang J., Hoshino T., Redner R.L., Kajigaya S., and Liu J.M. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 10860-10865
19. Gelmetti V., Zhang J., Fanelli M., Minucci S., Pelicci P.G., and Lazar M.A. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol. Cell. Biol. 18 (1998) 7185-7191
20. Lutterbach B., et al. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol. Cell. Biol. 18 (1998) 7176-7184
21. Klampfer L., Zhang J., Zelenetz A.O., Uchida H., and Nimer S.D. The AML1/ETO fusion protein activates transcription of BCL-2. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 14059-14064
22. Shimizu K., et al. AML1-MTG8 leukemic protein induces the expression of granulocyte colony-stimulating factor (G-CSF) receptor through the up-regulation of CCAAT/enhancer binding protein epsilon. Blood 96 (2000) 288-296
23. Rhoades K.L., et al. Synergistic up-regulation of the myeloid-specific promoter for the macrophage colony-stimulating factor receptor by AML1 and the t(8;21) fusion protein may contribute to leukemogenesis. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 11895-11900
24. Yan M., et al. Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 17186-17191
25. Yan M., et al. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nat. Med. 12 (2006) 945-949
26. Lutterbach B., Sun D., Schuetz J., and Hiebert S.W. The MYND motif is required for repression of basal transcription from the multidrug resistance 1 promoter by the t(8;21) fusion protein. Mol. Cell. Biol. 18 (1998) 3604-3611
27. Daley G.Q., and Baltimore D. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 9312-9316
28. Zhang D.E., Hetherington C.J., Chen H.M., and Tenen D.G. The macrophage transcription factor PU.1 directs tissue-specific expression of the macrophage colony-stimulating factor receptor. Mol. Cell. Biol. 14 (1994) 373-381
29. Thottassery J.V., Zambetti G.P., Arimori K., Schuetz E.G., and Schuetz J.D. p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 11037-11042
30. Linggi B., et al. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat. Med. 8 (2002) 743-750
31. Datto M.B., Yu Y., and Wang X.F. Functional analysis of the transforming growth factor beta responsive elements in the WAF1/Cip1/p21 promoter. J. Biol. Chem. 270 (1995) 28623-28628
32. Lenny N., Meyers S., and Hiebert S.W. Functional domains of the t(8;21) fusion protein, AML-1/ETO. Oncogene 11 (1995) 1761-1769
33. Petrovick M.S., Hiebert S.W., Friedman A.D., Hetherington C.J., Tenen D.G., and Zhang D.E. Multiple functional domains of AML1: PU.1 and C/EBPalpha synergize with different regions of AML1. Mol. Cell. Biol. 18 (1998) 3915-3925
34. Li Z., Van C.S., Qu C., Cavenee W.K., Zhang M.Q., and Ren B. A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 8164-8169
35. Andersson L.C., Jokinen M., and Gahmberg C.G. Induction of erythroid differentiation in the human leukaemia cell line K562. Nature 278 (1979) 364-365
36. Grosveld G., et al. The chronic myelocytic cell line K562 contains a breakpoint in bcr and produces a chimeric bcr/c-abl transcript. Mol. Cell. Biol. 6 (1986) 607-616
37. Sutherland J.A., Turner A.R., Mannoni P., McGann L.E., and Turc J.M. Differentiation of K562 leukemia cells along erythroid, macrophage, and megakaryocyte lineages. J. Biol. Response Mod. 5 (1986) 250-262
38. Leary J.F., Ohlsson-Wilhelm B.M., Giuliano R., LaBella S., Farley B., and Rowley P.T. Multipotent human hematopoietic cell line K562: lineage-specific constitutive and inducible antigens. Leuk. Res. 11 (1987) 807-815
39. Kohmura K., Miyakawa Y., Kawai Y., Ikeda Y., and Kizaki M. Different roles of p38 MAPK and ERK in STI571-induced multi-lineage differentiation of K562 cells. J. Cell. Physiol. 198 (2004) 370-376
40. Hsiang Y.H., Spencer D., Wang S., Speck N.A., and Raulet D.H. The role of viral enhancer "core" motif-related sequences in regulating T cell receptor-gamma and -delta gene expression. J. Immunol. 150 (1993) 3905-3916
41. Mao S., Frank R.C., Zhang J., Miyazaki Y., and Nimer S.D. Functional and physical interactions between AML1 proteins and an ETS protein, MEF: implications for the pathogenesis of t(8;21)-positive leukemias. Mol. Cell. Biol. 19 (1999) 3635-3644
42. Labialle S., Gayet L., Marthinet E., Rigal D., and Baggetto L.G. Transcriptional regulators of the human multidrug resistance 1 gene: recent views. Biochem. Pharmacol. 64 (2002) 943-948
43. Scotto K.W., and Johnson R.A. Transcription of the multidrug resistance gene MDR1: a therapeutic target. Mol. Interv. 1 (2001) 117-125
44. Peterson L.F., and Zhang D.E. The 8;21 translocation in leukemogenesis. Oncogene 23 (2004) 4255-4262
45. Rhoades K.L., et al. Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model. Blood 96 (2000) 2108-2115
46. Yuan Y., et al. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 10398-10403
47. Schwieger M., Lohler J., Friel J., Scheller M., Horak I., and Stocking C. AML1-ETO inhibits maturation of multiple lymphohematopoietic lineages and induces myeloblast transformation in synergy with ICSBP deficiency. J. Exp. Med. 196 (2002) 1227-1240
48. de Guzman C.G., et al. Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation. Mol. Cell. Biol. 22 (2002) 5506-5517
49. Higuchi M., O'Brien D., Kumaravelu P., Lenny N., Yeoh E.J., and Downing J.R. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell 1 (2002) 63-74
50. Hiebert S.W., Lutterbach B., and Amann J. Role of co-repressors in transcriptional repression mediated by the t(8;21), t(16;21), t(12;21), and inv(16) fusion proteins. Curr. Opin. Hematol. 8 (2001) 197-200
51. Leith C.P., et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 94 (1999) 1086-1099
52. Byrd J.C., et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100 (2002) 4325-4336
53. Grimwade D., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92 (1998) 2322-2333
54. Pearson L., et al. Multidrug resistance-1 (MDR1) expression and functional dye/drug efflux is highly correlated with the t(8;21) chromosomal translocation in pediatric acute myeloid leukemia. Leukemia 10 (1996) 1274-1282
55. Hug B.A., and Lazar M.A. ETO interacting proteins. Oncogene 23 (2004) 4270-4274
56. Johnson R.A., Shepard E.M., and Scotto K.W. Differential regulation of MDR1 transcription by the p53 family members. Role of the DNA binding domain. J. Biol. Chem. 280 (2005) 13213-13219